<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article225</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/AMPLIFY" style="display:block; margin-bottom:10px;">AMPLIFY Original</a></li>
<h2><strong>AMPLIFY</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Apixaban versus Conventional Therapy in Venous Thromboembolism".The New England Journal of Medicine. 2013. 369:799-808.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
Does a fixed-dose regimen of apixaban alone compare to conventional therapy with enoxaparin followed by warfarin in patients with acute venous thromboembolism?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
For the treatment of acute venous thromboembolism, apixaban was noninferior to conventional therapy and was associated with significantly less bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/>
Updated guidelines now need to consider the evidence from this trial when prescribing therapy for acute venous thromboembolism.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Multicenter, double-blind, randomized, controlled trial<br/>
- N=5395 patients with acute venous thromboembolism<br/>
- Apixaban group (n=2609)<br/>
- Conventional therapy group (n=2635)<br/>
- Setting: 358 centers in 28 countries<br/>
- Enrollment: August 2008 to August 2012<br/>
- Mean follow-up: 6 months<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Recurrence of symptomatic venous thromboembolism or death related to venous thromboembolism<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
<br/>
- Age ≥18 years<br/>
- Symptomatic proximal deep-vein thrombosis or pulmonary embolism (with or without deep-vein thrombosis)<br/>
<br/>
Exclusion Criteria<br/>
<br/>
- Active bleeding or high risk of bleeding<br/>
- Cancer with planned long-term low-molecular-weight heparin therapy<br/>
- Provoked venous thromboembolism without a persistent risk factor for recurrence<br/>
- Life expectancy less than 6 months<br/>
- Other indications for chronic anticoagulation or dual antiplatelet therapy<br/>
- Certain laboratory abnormalities<br/>
<br/>
Baseline Characteristics<br/>
<br/>
- Demographic and clinical characteristics were similar in both groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Apixaban group: 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months<br/>
- Conventional therapy group: Enoxaparin followed by warfarin for 6 months with adjustments to maintain INR between 2.0 and 3.0<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcome<br/>
<br/>
- Recurrence of symptomatic venous thromboembolism or death related to venous thromboembolism occurred in 2.3% of the apixaban group versus 2.7% of the conventional therapy group (P&lt;0.001 for noninferiority)<br/>
<br/>
Secondary Outcomes<br/>
<br/>
- Major bleeding occurred in 0.6% of the apixaban group versus 1.8% of the conventional therapy group (P&lt;0.001 for superiority)<br/>
- The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the apixaban group versus 9.7% of the conventional therapy group (P&lt;0.001)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
<br/>
- Further information is needed pertaining to the efficacy and safety of apixaban in patients with cancer, low body weight, or a creatinine clearance of less than 50 ml per minute.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
- The study was funded by Pfizer and Bristol-Myers Squibb.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
- The full text of the study is available at NEJM.org with supplementary materials detailing the protocol and full trial appendix.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
